Related Experiment Videos
[Neonatal malignant tumors. Apropos of 75 cases]
C Teinturier1, C Kalifa, O Hartmann
1Service d'Oncologie Pédiatrique, Institut Gustave-Roussy, Villejuif.
Insights
This study analyzed 75 neonates with malignant solid tumors, finding a 77% survival rate. Neuroblastomas showed the best prognosis, highlighting the need for treatment strategies that minimize long-term side effects in pediatric oncology.
Area of Science:
- Pediatric Oncology
- Neonatal Malignancies
Context:
- Malignant solid tumors in neonates are rare, accounting for 1.7% of pediatric oncology cases.
- This study reviewed 75 neonates treated between 1975 and 1986.
Purpose:
- To analyze the characteristics, treatment, and outcomes of malignant solid tumors in neonates.
- To evaluate the survival rates and identify factors influencing prognosis in this population.
Summary:
- Neuroblastomas were the most common diagnosis (62%), followed by mesenchymal tumors (20%) and germ cell tumors (12%).
- Treatment modalities included surgery (63 patients), chemotherapy (43 patients), and radiotherapy (18 patients).
- The overall 5-year crude survival rate was 77%, with neuroblastomas achieving an 89% survival rate.
Impact:
- Neonatal age presents unique challenges regarding immediate tolerance and long-term sequelae.
- Therapeutic strategies should balance efficacy with the reduction of delayed adverse effects, considering the generally favorable prognosis of many neonatal tumors.
Abstract:
From 1975 to 1986, 75 neonates were treated at the Institute Gustave-Roussy for a malignant solid tumor, comprising 1.7% of the overall oncopediatric population treated during the same period of time. Of these 75 patients, 47 (62%) presented with neuroblastomas, 15 (20%) with mesenchymal tumors, 9 (12%) with germ cell tumors and 4 with various other types of tumors. Treatment consisted of surgery in 63 patients, chemotherapy in 43 and radiotherapy in 18. The 5 year crude survival rate was 77%. Neuroblastomas did the best with a crude survival rate of 89%. The young age of the patients resulted in two types of problems: immediate tolerance and long term sequelae. The therapeutic regimen should take into account the good prognosis of the majority of these tumors in order to decrease delayed effects.